Cingulate Inc. (CING) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Cingulate Inc.
Address
1901 West 47th Place
Kansas City, KS 66205
United States of America (the)
Phone
913 942 2300
Website
Sector
Healthcare
Industry
Biotechnology
Employees
14
First IPO Date
December 08, 2021
Key Executives
| Name | Title | Pay | Year Born |
| Shane J. Schaffer | Co-Founder, Chief Executive Officer & Chairman of the Board | 794,374 | 1975 |
| Matthew N. Brams | Co-Founder, Executive Vice President & Chief Medical Officer | 206,313 | 1964 |
| Jennifer L. Callahan | Executive VP, CFO & Secretary | 619,505 | 1971 |
| Raul R. Silva | Co-Founder, Executive Vice President & Chief Science Officer | 0 | 1958 |
| Downey Bryan Wade | Executive VP & Chief Commercial Officer | 0 | 1972 |
| Thomas Dalton | Vice President of Investor & Public Relations | 0 | N/A |
Description
Cingulate Inc. is a biopharmaceutical enterprise currently in its clinical development phase, dedicated to devising therapeutic options for attention-deficit/hyperactivity disorder (ADHD). Leading its pipeline for ADHD are two drug candidates: CTx-1301 (dexmethylphenidate), which is currently progressing through Phase 3 clinical trials, and CTx-1302 (dextroamphetamine). The company is also engaged in the advancement of CTx-2103, a candidate intended for the management of anxiety disorders. Founded in 2012, Cingulate Inc. maintains its corporate headquarters in Kansas City, Kansas.
